## Gema Moreno-Bueno

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4803973/publications.pdf Version: 2024-02-01

		22153	19749
119	14,147	59	117
papers	citations	h-index	g-index
121	121	121	21710
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nature Medicine, 2012, 18, 883-891.	30.7	3,098
2	Epithelial-Mesenchymal Transition in Breast Cancer Relates to the Basal-like Phenotype. Cancer Research, 2008, 68, 989-997.	0.9	934
3	Metastatic Colonization Requires the Repression of the Epithelial-Mesenchymal Transition Inducer Prrx1. Cancer Cell, 2012, 22, 709-724.	16.8	832
4	Transcriptional regulation of cell polarity in EMT and cancer. Oncogene, 2008, 27, 6958-6969.	5.9	528
5	Correlation of Snail expression with histological grade and lymph node status in breast carcinomas. Oncogene, 2002, 21, 3241-3246.	5.9	522
6	Genetic Profiling of Epithelial Cells Expressing E-Cadherin Repressors Reveals a Distinct Role for Snail, Slug, and E47 Factors in Epithelial-Mesenchymal Transition. Cancer Research, 2006, 66, 9543-9556.	0.9	285
7	Combined Epidermal Growth Factor Receptor Targeting with the Tyrosine Kinase Inhibitor Gefitinib (ZD1839) and the Monoclonal Antibody Cetuximab (IMC-C225). Clinical Cancer Research, 2004, 10, 6487-6501.	7.0	273
8	Abnormalities of the APC/ $\hat{I}^2$ -catenin pathway in endometrial cancer. Oncogene, 2002, 21, 7981-7990.	5.9	252
9	β-Catenin Expression Pattern in Stage I and II Ovarian Carcinomas. American Journal of Pathology, 1999, 155, 527-536.	3.8	217
10	Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer. Modern Pathology, 2007, 20, 474-481.	5.5	209
11	<scp>EMT</scp> : Present and future in clinical oncology. Molecular Oncology, 2017, 11, 718-738.	4.6	205
12	Microâ€RNA signature of the epithelial–mesenchymal transition in endometrial carcinosarcoma. Journal of Pathology, 2011, 223, 72-80.	4.5	194
13	Lysyl Oxidase–Like 2 as a New Poor Prognosis Marker of Squamous Cell Carcinomas. Cancer Research, 2008, 68, 4541-4550.	0.9	192
14	Epigenetic and genetic alterations of <i>APC</i> and <i>CDH1</i> genes in lobular breast cancer: Relationships with abnormal Eâ€cadherin and catenin expression and microsatellite instability. International Journal of Cancer, 2003, 106, 208-215.	5.1	186
15	Cytoplasmic localization of p120ctn and E-cadherin loss characterize lobular breast carcinoma from preinvasive to metastatic lesions. Oncogene, 2004, 23, 3272-3283.	5.9	185
16	The morphological and molecular features of the epithelial-to-mesenchymal transition. Nature Protocols, 2009, 4, 1591-1613.	12.0	185
17	SNAI1 Is Required for Tumor Growth and Lymph Node Metastasis of Human Breast Carcinoma MDA-MB-231 Cells. Cancer Research, 2007, 67, 11721-11731.	0.9	184
18	Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. Molecular Cancer, 2010, 9, 196.	19.2	156

#	Article	IF	CITATIONS
19	Tiling Path Genomic Profiling of Grade 3 Invasive Ductal Breast Cancers. Clinical Cancer Research, 2009, 15, 2711-2722.	7.0	152
20	Lysyl oxidaseâ€like 2 (LOXL2), a new regulator of cell polarity required for metastatic dissemination of basalâ€like breast carcinomas. EMBO Molecular Medicine, 2011, 3, 528-544.	6.9	150
21	Endometrial carcinoma: molecular alterations involved in tumor development and progression. Oncogene, 2013, 32, 403-413.	5.9	148
22	Role of microRNA in epithelial to mesenchymal transition and metastasis and clinical perspectives. Cancer Management and Research, 2014, 6, 205.	1.9	144
23	Gasdermin-B Promotes Invasion and Metastasis in Breast Cancer Cells. PLoS ONE, 2014, 9, e90099.	2.5	141
24	β-Catenin Expression Pattern, β-Catenin Gene Mutations, and Microsatellite Instability in Endometrioid Ovarian Carcinomas and Synchronous Endometrial Carcinomas. Diagnostic Molecular Pathology, 2001, 10, 116-122.	2.1	138
25	Molecular profiling of docetaxel cytotoxicity in breast cancer cells: uncoupling of aberrant mitosis and apoptosis. Oncogene, 2007, 26, 2902-2913.	5.9	127
26	beta-catenin expression in pilomatrixomas. Relationship with beta-catenin gene mutations and comparison with beta-catenin expression in normal hair follicles. British Journal of Dermatology, 2001, 145, 576-581.	1.5	122
27	Abnormalities of E- and P-cadherin and catenin (β-, γ-catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia. Journal of Pathology, 2003, 199, 471-478.	4.5	121
28	Lysyl Oxidase–like Protein LOXL2 Promotes Lung Metastasis of Breast Cancer. Cancer Research, 2017, 77, 5846-5859.	0.9	117
29	Exosome-mimetic nanoplatforms for targeted cancer drug delivery. Journal of Nanobiotechnology, 2019, 17, 85.	9.1	117
30	Prostaglandin E2 Leads to the Acquisition of DNMT3A-Dependent Tolerogenic Functions in Human Myeloid-Derived Suppressor Cells. Cell Reports, 2017, 21, 154-167.	6.4	116
31	The class I bHLH factors E2-2A and E2-2B regulate EMT. Journal of Cell Science, 2009, 122, 1014-1024.	2.0	110
32	Cyclin D1 gene (CCND1) mutations in endometrial cancer. Oncogene, 2003, 22, 6115-6118.	5.9	107
33	Microsatellite instability, MLH-1 promoter hypermethylation, and frameshift mutations at coding mononucleotide repeat microsatellites in ovarian tumors. Cancer, 2001, 92, 2829-2836.	4.1	103
34	Snai1 and Snai2 collaborate on tumor growth and metastasis properties of mouse skin carcinoma cell lines. Oncogene, 2008, 27, 4690-4701.	5.9	101
35	Inactivation of the Candidate Tumor Suppressor Par-4 in Endometrial Cancer. Cancer Research, 2007, 67, 1927-1934.	0.9	100
36	Role of Cannabinoid Receptor CB2 in HER2 Pro-oncogenic Signaling in Breast Cancer. Journal of the National Cancer Institute, 2015, 107, djv077.	6.3	98

#	Article	IF	CITATIONS
37	The EMT signaling pathways in endometrial carcinoma. Clinical and Translational Oncology, 2012, 14, 715-720.	2.4	95
38	Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas. Journal of Clinical Pathology, 2006, 60, 1006-1012.	2.0	93
39	LOXL2 drives epithelial-mesenchymal transition via activation of IRE1-XBP1 signalling pathway. Scientific Reports, 2017, 7, 44988.	3.3	93
40	EFNA3 long noncoding RNAs induced by hypoxia promote metastatic dissemination. Oncogene, 2015, 34, 2609-2620.	5.9	91
41	Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer. Molecular Cancer, 2014, 13, 223.	19.2	88
42	The Prognostic Significance of P-Cadherin in Infiltrating Ductal Breast Carcinoma. Modern Pathology, 2001, 14, 650-654.	5.5	85
43	Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer. Oncotarget, 2016, 7, 56295-56308.	1.8	83
44	Lysyl oxidaseâ€like 2 represses Notch1 expression in the skin to promote squamous cell carcinoma progression. EMBO Journal, 2015, 34, 1090-1109.	7.8	79
45	Intracellular Delivery of an Antibody Targeting Gasdermin-B Reduces HER2 Breast Cancer Aggressiveness. Clinical Cancer Research, 2019, 25, 4846-4858.	7.0	79
46	LOXL2 in epithelial cell plasticity and tumor progression. Future Oncology, 2012, 8, 1095-1108.	2.4	78
47	Distinct Molecular Alterations in Complex Endometrial Hyperplasia (CEH) With and Without Immature Squamous Metaplasia (Squamous Morules). American Journal of Surgical Pathology, 2005, 29, 1322-1329.	3.7	75
48	Lysyl oxidase-like 2 (LOXL2) and E47 EMT factor: novel partners in E-cadherin repression and early metastasis colonization. Oncogene, 2015, 34, 951-964.	5.9	75
49	Transcriptional profiling of MCF7 breast cancer cells in response to 5-Fluorouracil: Relationship with cell cycle changes and apoptosis, and identification of novel targets of p53. International Journal of Cancer, 2006, 119, 1164-1175.	5.1	74
50	Pathogenetic Pathways in Ovarian Endometrioid Adenocarcinoma. American Journal of Surgical Pathology, 2009, 33, 1157-1163.	3.7	72
51	Expression of cadherins and catenins correlates with distinct histologic types of ovarian carcinomas. Human Pathology, 2006, 37, 1042-1049.	2.0	69
52	High frequency of β-catenin mutations in borderline endometrioid tumours of the ovary. Journal of Pathology, 2006, 208, 708-713.	4.5	67
53	A Novel Human Ghrelin Variant (In1-Ghrelin) and Ghrelin-O-Acyltransferase Are Overexpressed in Breast Cancer: Potential Pathophysiological Relevance. PLoS ÓNE, 2011, 6, e23302.	2.5	67
54	JunD is involved in the antiproliferative effect of Δ9-tetrahydrocannabinol on human breast cancer cells. Oncogene, 2008, 27, 5033-5044.	5.9	66

#	Article	IF	CITATIONS
55	A core microRNA signature associated with inducers of the epithelial-to-mesenchymal transition. Journal of Pathology, 2014, 232, 319-329.	4.5	66
56	The new truncated somatostatin receptor variant sst5TMD4 is associated to poor prognosis in breast cancer and increases malignancy in MCF-7 cells. Oncogene, 2012, 31, 2049-2061.	5.9	65
57	MicroRNA-Dependent Regulation of Transcription in Non-Small Cell Lung Cancer. PLoS ONE, 2014, 9, e90524.	2.5	65
58	Gene expression profiling of breast cancer cells in response to gemcitabine: NF-κB pathway activation as a potential mechanism of resistance. Breast Cancer Research and Treatment, 2007, 102, 157-172.	2.5	63
59	Sporadic Invasive Breast Carcinomas With Medullary Features Display a Basal-like Phenotype. American Journal of Surgical Pathology, 2007, 31, 501-508.	3.7	62
60	Functional characterization of E- and P-cadherin in invasive breast cancer cells. BMC Cancer, 2009, 9, 74.	2.6	61
61	LOXL2 catalytically inactive mutants mediate epithelial-to-mesenchymal transition. Biology Open, 2014, 3, 129-137.	1.2	60
62	Cyclin E gene ( <i>CCNE</i> ) amplification and <i>hCDC4</i> mutations in endometrial carcinoma. Journal of Pathology, 2003, 201, 589-595.	4.5	56
63	β- And γ-catenin expression in endometrial carcinoma. Relationship with clinicopathological features and microsatellite instability. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2001, 438, 464-469.	2.8	52
64	Zeb1 and <scp>S</scp> nail1 engage mi <scp>R</scp> â€200f transcriptional and epigenetic regulation during <scp>EMT</scp> . International Journal of Cancer, 2015, 136, E62-73.	5.1	52
65	MicroRNA-654-5p suppresses ovarian cancer development impacting on MYC, WNT and AKT pathways. Oncogene, 2019, 38, 6035-6050.	5.9	49
66	E47 and Id1 Interplay in Epithelial-Mesenchymal Transition. PLoS ONE, 2013, 8, e59948.	2.5	46
67	Activated leukocyte cell adhesion molecule ( <scp>ALCAM</scp> ) is a marker of recurrence and promotes cell migration, invasion, and metastasis in earlyâ€stage endometrioid endometrial cancer. Journal of Pathology, 2017, 241, 475-487.	4.5	42
68	Contribution of Epithelial Plasticity to Therapy Resistance. Journal of Clinical Medicine, 2019, 8, 676.	2.4	42
69	β-Catenin expression pattern in primary oesophageal squamous cell carcinoma. Relationship with clinicopathologic features and clinical outcome. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2000, 437, 599-604.	2.8	41
70	Simultaneous inactivation of Par-4 and PTEN in vivo leads to synergistic NF-κB activation and invasive prostate carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 12962-12967.	7.1	40
71	Therapeutic targeting of HER2–CB <sub>2</sub> R heteromers in HER2-positive breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 3863-3872.	7.1	40
72	Annexinâ€A2 as predictor biomarker of recurrent disease in endometrial cancer. International Journal of Cancer, 2015, 136, 1863-1873.	5.1	39

#	Article	IF	CITATIONS
73	Tissue Microarray Immunohistochemical Expression Analysis of Mismatch Repair (hMLH1 and hMSH2) Tj ETQq1	0.784314 5.5	1 rgBT /Over 38
74	Microsatellite Instability. Modern Pathology, 2003, 16, 1148-1158. Genetic analysis of uterine aspirates improves the diagnostic value and captures the intra-tumor heterogeneity of endometrial cancers. Modern Pathology, 2017, 30, 134-145.	5.5	36
75	Molecular alterations associated with cyclin d1 overexpression in endometrial cancer. International Journal of Cancer, 2004, 110, 194-200.	5.1	35
76	Premalignant SOX2 overexpression in the fallopian tubes of ovarian cancer patients: Discovery and validation studies. EBioMedicine, 2016, 10, 137-149.	6.1	34
77	Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition. Oncogene, 2017, 36, 2737-2749.	5.9	34
78	The tumor suppressor ING1 contributes to epigenetic control of cellular senescence. Aging Cell, 2011, 10, 158-171.	6.7	32
79	KSR1 Is Overexpressed in Endometrial Carcinoma and Regulates Proliferation and TRAIL-Induced Apoptosis by Modulating FLIP Levels. American Journal of Pathology, 2011, 178, 1529-1543.	3.8	30
80	Molecular events in endometrial carcinosarcomas and the role of high mobility group AT-hook 2 in endometrial carcinogenesis. Human Pathology, 2013, 44, 244-254.	2.0	30
81	MicroRNAs as prognostic markers in ovarian cancer. Molecular and Cellular Endocrinology, 2014, 390, 73-84.	3.2	30
82	Chromatin remodelling and DNA repair genes are frequently mutated in endometrioid endometrial carcinoma. International Journal of Cancer, 2017, 140, 1551-1563.	5.1	30
83	Extracellular Vesicles-Based Biomarkers Represent a Promising Liquid Biopsy in Endometrial Cancer. Cancers, 2019, 11, 2000.	3.7	30
84	Sin3b Interacts with Myc and Decreases Myc Levels. Journal of Biological Chemistry, 2014, 289, 22221-22236.	3.4	29
85	A Role for CXCR4 in Peritoneal and Hematogenous Ovarian Cancer Dissemination. Molecular Cancer Therapeutics, 2018, 17, 532-543.	4.1	28
86	Interplay between YB-1 and IL-6 promotes the metastatic phenotype in breast cancer cells. Oncotarget, 2015, 6, 38239-38256.	1.8	28
87	Human equilibrative nucleoside transporter-1 (hENT1) is required for the transcriptomic response of the nucleoside-derived drug 5â€2-DFUR in breast cancer MCF7 cells. Biochemical Pharmacology, 2006, 72, 1646-1656.	4.4	27
88	Tumor Heterogeneity in Endometrial Carcinoma: Practical Consequences. Pathobiology, 2018, 85, 35-40.	3.8	26
89	Circulating Tumor Cells Characterization Revealed TIMP1 as a Potential Therapeutic Target in Ovarian Cancer. Cells, 2020, 9, 1218.	4.1	25
90	PAI-1 and functional blockade of SNAI1 in breast cancer cell migration. Breast Cancer Research, 2008, 10, R100.	5.0	23

#	Article	IF	CITATIONS
91	A role for the transducer of the Hippo pathway, TAZ, in the development of aggressive types of endometrial cancer. Modern Pathology, 2015, 28, 1492-1503.	5.5	23
92	Genomic Profiling of Uterine Aspirates and cfDNA as an Integrative Liquid Biopsy Strategy in Endometrial Cancer. Journal of Clinical Medicine, 2020, 9, 585.	2.4	23
93	Clinicopathological and molecular analysis of endometrial carcinoma associated with tamoxifen. Modern Pathology, 2008, 21, 925-936.	5.5	22
94	Low Frequency of BRAF Mutations in Endometrial and in Cervical Carcinomas. Clinical Cancer Research, 2006, 12, 3865-3866.	7.0	20
95	In1-ghrelin splicing variant is associated with reduced disease-free survival of breast cancer patients and increases malignancy of breast cancer cells lines. Carcinogenesis, 2018, 39, 447-457.	2.8	19
96	A 9-protein biomarker molecular signature for predicting histologic type in endometrial carcinoma by immunohistochemistry. Human Pathology, 2014, 45, 2394-2403.	2.0	18
97	E2A Modulates Stemness, Metastasis, and Therapeutic Resistance of Breast Cancer. Cancer Research, 2021, 81, 4529-4544.	0.9	18
98	ING4 regulates a secretory phenotype in primary fibroblasts with dual effects on cell proliferation and tumor growth. Oncogene, 2014, 33, 1945-1953.	5.9	17
99	Looking for a Better Characterization of Triple-Negative Breast Cancer by Means of Circulating Tumor Cells. Journal of Clinical Medicine, 2020, 9, 353.	2.4	17
100	Correlation of p53 oncoprotein expression with chemotherapy response in small cell lung carcinomas. Lung Cancer, 2001, 34, 67-74.	2.0	16
101	"New―molecular taxonomy in breast cancer. Clinical and Translational Oncology, 2008, 10, 777-785.	2.4	16
102	Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression. BMC Cancer, 2015, 15, 940.	2.6	16
103	The truncated somatostatin receptor sst5TMD4 stimulates the angiogenic process and is associated to lymphatic metastasis and disease-free survival in breast cancer patients. Oncotarget, 2016, 7, 60110-60122.	1.8	16
104	The homeoprotein SIX1 controls cellular senescence through the regulation of p16INK4A and differentiation-related genes. Oncogene, 2016, 35, 3485-3494.	5.9	15
105	The Ras-related gene ERAS is involved in human and murine breast cancer. Scientific Reports, 2018, 8, 13038.	3.3	15
106	Impact of notch signaling on the prognosis of patients with head and neck squamous cell carcinoma. Oral Oncology, 2020, 110, 105003.	1.5	12
107	Insight updating of the molecular hallmarks in ovarian carcinoma. European Journal of Cancer, Supplement, 2020, 15, 16-26.	2.2	12
108	Characterisation of tumoral markers correlated with ErbB2 (HER2/ <b><i>Neu</i></b> ) overexpression and metastasis in breast cancer. Proteomics - Clinical Applications, 2008, 2, 1313-1326.	1.6	11

Gema Moreno-Bueno

#	ARTICLE	IF	CITATIONS
109	Clinical validation of a novel quantitative assay for the detection of MGMT methylation in glioblastoma patients. Clinical Epigenetics, 2021, 13, 52.	4.1	9
110	Intratumor genetic heterogeneity and clonal evolution to decode endometrial cancer progression. Oncogene, 2022, 41, 1835-1850.	5.9	9
111	Prostaglandin F2α-induced Prostate Transmembrane Protein, Androgen Induced 1 mediates ovarian cancer progression increasing epithelial plasticity. Neoplasia, 2019, 21, 1073-1084.	5.3	8
112	Isobolographic Analysis Demonstrates the Additive and Synergistic Effects of Gemcitabine Combined with Fucoidan in Uterine Sarcomas and Carcinosarcoma Cells. Cancers, 2020, 12, 107.	3.7	8
113	Gemcitabine and Selected mTOR Inhibitors in Uterine Sarcomas and Carcinosarcoma Cells- an Isobolographic Analysis. International Journal of Medical Sciences, 2020, 17, 2987-2997.	2.5	8
114	Loxl3 Promotes Melanoma Progression and Dissemination Influencing Cell Plasticity and Survival. Cancers, 2022, 14, 1200.	3.7	8
115	Re: Scholtenet al. Nuclearβ-catenin is a molecular feature of type I endometrial carcinoma.J Pathol 2003; 201: 460–465. Journal of Pathology, 2004, 202, 511-512.	4.5	7
116	Cancer network activity associated with therapeutic response and synergism. Genome Medicine, 2016, 8, 88.	8.2	7
117	Loss of Snail2 favors skin tumor progression by promoting the recruitment of myeloid progenitors. Carcinogenesis, 2015, 36, 585-597.	2.8	5
118	Biological Effects of Temsirolimus on the mTOR Pathway in Endometrial Carcinoma. International Journal of Gynecological Cancer, 2016, , 1.	2.5	5
119	Isolation and characterization of casein kinase I from Dictyostelium discoideum. Biochemical Journal, 2000, 349, 527.	3.7	3